Additionally, we tested the impact of EHMT2 inhibition on NK cell-mediated pancreatic cancer eradication, which is another cancer type for which adaptive immune checkpoint blockade therapies have not worked as desired (Royal et al, 2010). Here, EHMT2 is linked to pancreatic neoplasm.